Small molecule · developed by Sunshine Lake Pharma Co.
HEC53856 is an oral tablet studied in chemotherapy-induced anemia and in non-myeloid malignancies.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07891377 | Phase 2 | Chemotherapy-induced Anemia | Not yet recruiting | SBFM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Chemotherapy-induced AnemiaNon-Myeloid Malignancy
Updated Nov 1, 2026. Something wrong or missing? Report it on the SBFM page.
See SBFM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SBFM catalysts and pipeline →